MedTrace Logo

Clinical Study of NK Cells in the Treatment of Severe Endometriosis

NCT03948828 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-05-14

No results posted yet for this study

Summary

Dysfunction of natural koller cells (NK cells) is an important factor in the development of endometriosis. NK cell therapy was applied to treat severe endometriosis, which is an exploration of the pathogenesis of this refractory disease.

Conditions

  • NK Cell Mediated Immunity
  • Endometriosis

Interventions

BIOLOGICAL

Autologous NK cell therapy

After conventional treatment, the patients were treated with autologous NK cells.

DRUG

GnRHa combained with reverse addition therapy

Postoperative patients were treated with GnRHa combined with reverse addition treatment.

Sponsors & Collaborators

  • Shenzhen People's Hospital

    lead OTHER

Principal Investigators

  • Hui Qi, M.D · Shen Zhen People's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2022-05-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03948828 on ClinicalTrials.gov